Mark D. McKee
- Oncology top 2%
- PARP inhibition in cancer therapy 16
- CAR-T cell therapy research 8
- Colorectal Cancer Treatments and Studies 6
- Cancer Treatment and Pharmacology 6
- Hepatology top 2%
- Immunology top 2%
- Immunotherapy and Immune Responses 7
- T-cell and B-cell Immunology 6
- Cancer Research top 5%
-
- DNA Repair Mechanisms 6
-
- Lung Cancer Treatments and Mutations 6
- Co-authors
- Amy PetersonYuru MengYuanyuan ZhaHelena HarlinMaria TretiakovaCraig L. SlingluffThomas F. GajewskiDanielle Sullivan
- Cited by
- OncologyHepatologyImmunology
- Journals
- Journal of Clinical Oncology (15 papers)Journal of Immunotherapy (5 papers)Annals of Oncology (4 papers)
- Partner nations
- United StatesRussiaGermany
In The Last Decade
Mark D. McKee
44 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 1.6k
- Hepatology 453
- Immunology 951
- Cancer Research 490
- Pathology and Forensic Medicine 361
Countries citing papers authored by Mark D. McKee
This map shows the geographic impact of Mark D. McKee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. McKee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. McKee more than expected).
Fields of papers citing papers by Mark D. McKee
This network shows the impact of papers produced by Mark D. McKee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. McKee. The network helps show where Mark D. McKee may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark D. McKee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 18 | |
| 2 | 2018 | 58 | |
| 3 | 2017 | 1 | |
| 4 | 2015 | 69 | |
| 5 | 2014 | 17 | |
| 6 | Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trialbreakdown → | 2014 | 465 |
| 7 | 2014 | 3 | |
| 8 | Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitmentbreakdown → | 2009 | 872 |
| 9 | 2009 | 26 | |
| 10 | 2009 | 58 | |
| 11 | 2008 | 9 | |
| 12 | 2007 | 2 | |
| 13 | 2007 | 6 | |
| 14 | 2006 | 32 | |
| 15 | 2005 | 27 | |
| 16 | 2003 | 46 | |
| 17 | 2002 | 3 | |
| 18 | 1999 | 88 | |
| 19 | 1999 | 12 | |
| 20 | 1997 | 12 |
About Mark D. McKee
Mark D. McKee is a scholar working on Oncology, Immunology, Hepatology, Transplantation and Hematology, having authored 46 papers that have together received 2.6k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (16 papers), CAR-T cell therapy research (8 papers), Immunotherapy and Immune Responses (7 papers), DNA Repair Mechanisms (6 papers), Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (6 papers) and T-cell and B-cell Immunology (6 papers). The work is most often cited by research in Oncology (1.6k citations), Hepatology (453 citations), Immunology (951 citations), Cancer Research (490 citations) and Pathology and Forensic Medicine (361 citations). Mark D. McKee has collaborated with scholars based in United States, Russia and Germany. Frequent co-authors include Amy Peterson, Yuru Meng, Yuanyuan Zha, Helena Harlin, Maria Tretiakova, Craig L. Slingluff, Thomas F. Gajewski, Danielle Sullivan, Michael I. Nishimura and Jiang Qian. Their work appears in journals such as Journal of Clinical Oncology, Journal of Immunotherapy, Annals of Oncology, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.